TARA Biosystems Partners with Scipher Medicine®
November 3, 2021
News
Scipher to use proprietary patient molecular data analyzed by its SpectraTM platform to identify novel drug targets. TARA Biosystems to progress selected targets in its BiowireTM II drug discovery platform for cardiac laminopathies. Partnership set to reduce target discovery and validation from years down …
VantAI and TARA Biosystems Partner to Discover New Medicines
July 28, 2020
News
NEW YORK, NY - (EurekAlert) - VantAI and TARA Biosystems today announced the launch of a biology-driven, AI-enabled collaboration for accelerated cardiac drug development. The partnership will leverage TARA’s state-of-the-art in vitro human …
TARA Biosystems Announces $10 Million Series A2 Financing to Expand its Cardiac Disease Drug Discovery and Development Capabilities
June 23, 2020
News
NEW YORK, NY - (BUSINESS WIRE) - TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 …
Heart-on-a-Chip Technology Predicts Preclinical Systolic and Diastolic in vivo Observations for Novel Cardiac Drug in Development
November 18, 2019
News
NEW YORK, NY - (Newswire.com) - TARA Biosystems, Inc. today reported in vivo and in vitro functional data from a
TARA Biosystems Launches Cardiotype.Ca™ Cardiac Calcium Signaling Assay: In Vitro Assay Accelerates Drug Development in Human-Relevant Heart Models
September 23, 2019
News
NEW YORK, NY (Newswire.com) - TARA Biosystems, Inc. launched Cardiotype.Ca™, its in vitro system for assessing cardiac calcium signaling. The new assay can be used independently or in combination with TARA’s <…
Heart-on-a-Chip Mimics Drug Response Seen in Humans: In Vitro Approach Provides Predictive Platform for Human-Based Drug Discovery
August 6, 2019
News
NEW YORK, N.Y. (Newswire.com)— Researchers from TARA Biosystems, Inc. and GlaxoSmithKline (GSK) today published data demonstrating that TARA’s engineered heart-on-a-chip system replicated drug responses found in adult humans. The …
TARA Secures Exclusive Worldwide License to Columbia University Intellectual Property relating to Engineered Human Cardiac Tissues
May 28, 2019
News
NEW YORK, N.Y. (Newswire.com)— TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the execution of an exclusive worldwide license agreement with Columbia …
TARA Announces Issuance of US Patent for Biowire™ II Platform
May 14, 2019
News
New York, NY, (Newswire.com) - TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced that the United States Patent and Trademark Office (USPTO) has …
TARA Biosystems Biowire™ II Heart-on-a-Chip Platform Published in CELL
January 24, 2019
News
NEW YORK, (Newswire.com) TARA Biosystems, Inc., a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the first peer-reviewed publication of its Biowire™ II platform by a team of …
TARA Biosystems and Insilico Medicine Announce Drug Discovery Collaboration for Cardiac Disease
January 7, 2019
News
New York – TARA Biosystems, Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and risk assessment applications and Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines for age-related diseases, announced today the launch of a collaboration to discover and develop novel therapies for …